NRx Pharmaceuticals (NRXP) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of NRx Pharmaceuticals (NASDAQ: NRXP) in the last few weeks:

• 3/24/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
• 3/20/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
• 3/17/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
• 3/14/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
• 1/28/2025 – NRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ NRXP remained flat at $2.07 during trading hours on Thursday. 112,686 shares of the company traded hands, compared to its average volume of 451,493. NRx Pharmaceuticals, Inc. has a 1 year low of $1.10 and a 1 year high of $6.01. The firm’s 50 day simple moving average is $2.66 and its two-hundred day simple moving average is $2.04. The firm has a market capitalization of $35.02 million, a P/E ratio of -0.97 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Research analysts predict that NRx Pharmaceuticals, Inc. will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in NRXP. Townsquare Capital LLC acquired a new position in shares of NRx Pharmaceuticals during the third quarter valued at about $25,000. Anson Funds Management LP acquired a new position in NRx Pharmaceuticals during the 3rd quarter valued at approximately $241,000. Sassicaia Capital Advisers LLC purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth $33,000. AdvisorShares Investments LLC lifted its stake in shares of NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after buying an additional 180,229 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals during the fourth quarter valued at $61,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.